Assay Validation of High Quality Markers for Clinical Studies in Cancer
Funds analytically and clinically validating a cancer biomarker and its assay for detection, diagnosis, prognosis or treatment response.
A biomarker that looks promising in a lab is not the same as an assay a clinical laboratory can actually run and trust.
This notice funds two routes to closing that gap. A biphasic UH2/UH3 award, running up to five years, takes an assay through analytical validation first — up to two years, in the UH2 phase — and then clinical validation for up to three years in the UH3 phase, using well-annotate…
Analytical and clinical validation of molecular, cellular or imaging cancer biomarkers and their assays for detection, diagnosis, prognosis, monitoring, treatment-response prediction, prevention, control, or pharmacodynamic and toxicity measurement, through a biphasic UH2/UH3 award or a monophasic standalone UH3 award for an already analytically validated assay.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up